Buserelin

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Buserelin is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1984. DrugCentral lists 3 molecular targets, including GNRHR, Gnrhr and LHCGR. Recorded indications include Induction of final follicular maturation and Prevention of premature ovulation.

• Molecular targets: GNRHR, Gnrhr and LHCGR (3 listed in DrugCentral).
• Indications: Induction of final follicular maturation and Prevention of premature ovulation.
• ATC code: L02AE01 (Gonadotropin releasing hormone analogues).
• Molecular formula: C60H86N16O13; molecular weight 1239.45 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Induction of final follicular maturation
• Prevention of premature ovulation

Mechanism & targets

Molecular targets (3)

Target	Gene	Action	Activity
Gonadotropin-releasing hormone receptor	GNRHR	agonist	EC50 10.52
Gonadotropin-releasing hormone receptor	Gnrhr	agonist	EC50 10.05
Lutropin-choriogonadotropic hormone receptor	LHCGR	unknown	Kd 8.57

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2022-02-25	PMDA	—	Sanofi K.K.
1984-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
L02AE01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ENDOCRINE THERAPY › HORMONES AND RELATED AGENTS › Gonadotropin releasing hormone analogues

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Ovarian hyperstimulation syndrome	158.6

Chemical structure

• Molecular formula: C₆₀H₈₆N₁₆O₁₃
• Molecular weight: 1239.45 g/mol
• CAS number: —
• InChIKey: CUWODFFVMXJOKD-UVLQAERKSA-N
• PubChem CID: 50225

CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Buserelin used for?

DrugCentral lists the following indications for Buserelin: Induction of final follicular maturation and Prevention of premature ovulation.

How does Buserelin work?

Its molecular targets in DrugCentral include GNRHR (agonist), Gnrhr (agonist) and LHCGR.

When was Buserelin first approved?

Buserelin was first approved by the YEAR INTRODUCED in 1984.

What is the chemical formula of Buserelin?

Buserelin has the molecular formula C60H86N16O13 and a molecular weight of 1239.45 g/mol.

Sources

• DrugCentral drug card 436 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2106198 — compound record and bioactivity
• PubChem CID 50225 — chemical identifiers
• DrugBank DB06719 — drug record
• FDA UNII PXW8U3YXDV — substance identity
• UniProt P30968 (GNRHR) — target protein
• UniProt P22888 (LHCGR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.